Literature DB >> 8296792

Stability of factor VIII concentrates after reconstitution.

S Schulman1, S Gitel, U Martinowitz.   

Abstract

Adjusted-dose continuous infusion of factor VIII (F VIII) has recently been shown to reduce the doses of the factor in patients undergoing surgery by 50-75%. The main limitation of this method has been the instability of factor concentrates. All manufacturers are recommending infusion of the concentrate within hours after reconstitution. We studied the stability of 15 different lyophilized F VIII products. Reconstituted samples were stored for periods of 4, 24, and 72 hr and 1, 2, 3, and 4 weeks at temperatures of 4-8 degrees C, 20-23 degrees C, and 37 degrees C in their original glass containers and in plastic tubes and then frozen. Assays were performed in duplicate, using a one-stage clotting method and a chromogenic assay for F VIII, with all samples from a single concentrate in the same run. Activation of the coagulation factor occurred in some concentrates, more often at 4-8 degrees C than at 20-23 degrees C or 37 degrees C. The stability of all products was substantially better than that declared by the manufacturers. Several concentrates maintained factor activities above 80% of baseline for the entire period of 4 weeks at 4-8 degrees C or at 20-23 degrees C. The results demonstrate that many of the F VIII concentrates may be used for continuous infusion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8296792     DOI: 10.1002/ajh.2830450305

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  3 in total

1.  Correlation of rFVIII inactivation with aggregation in solution.

Authors:  Wei Wang; Drew N Kelner
Journal:  Pharm Res       Date:  2003-04       Impact factor: 4.200

2.  Progress of in vitro factor VIII coagulant activity from 0 to 8 hours after reconstitution.

Authors:  Ye Jee Shim; Kun Soo Lee; Uk Hyun Kim; Jin Kyung Suh; Sae Yun Baik; Shin Young Hyun
Journal:  Blood Res       Date:  2014-12-23

3.  Comparison of continuous infusion versus bolus injection of factor concentrates for blood management after total knee arthroplasty in patients with hemophilia.

Authors:  Young Shil Park; Won-Ju Shin; Kang-Il Kim
Journal:  BMC Musculoskelet Disord       Date:  2017-08-22       Impact factor: 2.362

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.